Jump to content

Ceralasertib

From Wikipedia, the free encyclopedia

Ceralasertib
Clinical data
Other namesAZD-6738
Legal status
Legal status
  • Investigational
Identifiers
  • imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
ECHA InfoCard100.232.607 Edit this at Wikidata
Chemical and physical data
FormulaC20H24N6O2S
Molar mass412.51 g·mol−1
3D model (JSmol)
  • C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](=N)(=O)C)C4=C5C=CNC5=NC=C4
  • InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1
  • Key:OHUHVTCQTUDPIJ-JYCIKRDWSA-N

Ceralasertib is an investigational new drug that is being evaluated for the treatment of cancer.[1] It is an ATR kinase inhibitor.[2]

References

[edit]
  1. ^ "Ceralasertib - AstraZeneca/University of Pennsylvania". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Mavroeidi D, Georganta A, Panagiotou E, Syrigos K, Souliotis VL (February 2024). "Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes". International Journal of Molecular Sciences. 25 (5): 2767. doi:10.3390/ijms25052767. PMC 10932434. PMID 38474014.